Aims-To investigate the presence of the macrophage associated antigen CD68 in non-haematopoietic tumours. Methods-Cytological specimens from non-macrophage derived tumours were stained using the alkaline phosphatase anti-alkaline phosphatase immunocytochemical method (APAAP) 
At the Fourth International Workshop on Human Leucocyte Differentiation Antigens (Vienna 1989), five different monoclonal antibodies were identified as pan-macrophage reagents recognising a 110 kilodalton glycoprotein and were designated as a new CD group CD68.' CD68 is the most macrophage-monocyte specific group of markers identified to date. In a detailed study of its distribution, however, small amounts were found in lymphocytes and in non-haematopoietic cells, such as renal tubules, and additionally it was detected in the vulval carcinoma cell line A431 and the melanoma cell line RVH42 1.
Immunocytochemistry can be particularly useful in resolving diagnostic problems relating to tumours of uncertain origin.3 In cytological specimens in particular, the need for accurate and objective characterisation of small groups of cells frequently arises, because the amount of material available is often limited or of suboptimal quality. In these cases a panel of monoclonal antibodies can be crucial for the correct characterisation of a poorly differentiated neoplasm. It is therefore essential that the monoclonal antibodies used are well characterised and that the full spectrum of cell types which they recognise is known, to avoid misleading interpretations.
This study was undertaken to investigate how specific the CD68 antigen is for cells of monocyte-macrophage origin in cytological samples, and hence to establish its diagnostic value in this context.
Methods
Sixty eight cytological specimens were examined; 16 of ascitic fluid, eight of pleural fluid, six fine needle aspirates of the breast, five fine needle aspirates of the liver, two fine needle aspirates of the pancreas, two fine needle aspirate of the lung, three fine needle aspirates from lymph nodes, one fine needle aspirate from the kidney and one from the prostate, one specimen of mid-stream urine and 23 fine needle aspirates from various sites of the body.
All specimens were received unfixed. Wet fixed as well as air dried smears were prepared, stained with the Papanicolaou and the Romanowsky methods, respectively, and processed for routine cytological diagnosis. Spare unfixed smears were prepared and stored at -20°C.
Three monoclonal antibodies that recognise the CD68 antigen were used. Monoclonal antibody Y1/82A was raised against phytohaemagglutinin activated peripheral blood monocytes,4 antibody KP 1 against a lysosomal fraction of human lung macrophages,5 and antibody EBM1 1 against isolated human lung macrophages.6 All antibodies were applied as undiluted tissue culture supernatant fluids.
An alkaline phosphatase anti-alkaline phosphatase (APAAP) immunocytochemical method was used, as described previously.-The alkaline phosphatase substrate was prepared with naphthol AS-MX phosphate (Sigma Catalogue No 4875) and Fast Red TR salt (Sigma Catalogue No Fl 500), and contained Levamisole to block endogenous enzyme activity.
Results
All three antibodies showed strong punctate cytoplasmic staining of all macrophages present in the samples studied (figs 1A, D), as CD68 reactivity of non-macrophage derived tumours in cytological specimens *# e' v. (fig 1 C) .
In the case of renal cell carcinoma ( fig  ID) all' reported two monocyte-macrophage associated antibodies, Ki-M3 and Ki-M7 (anti-CD 68), that reacted with all 19 cases of renal cell carcinomas which they studied. KP1 has also been reported to react with malignant melanomas14 and granular cell neoplasms,'5 although the single case that we studied was negative.
The reactivity with epithelial cells varied among the three monoclonal antibodies, with Y1/82A staining fewer cases more weakly than either KP1 or EBM 11. Overall, macrophage staining was much more prominent with all antibodies than was the staining of the tumour cells so that it was usually possible to differentiate the two cell types.
These results indicate that, although CD68 is a robust macrophage marker, immunocytochemical staining results on cytological specimens must be interpreted with caution. If possible, anti-CD68 reagents should be used in combination with other myeloid and antimacrophage antibodies as part of a panel of antibodies to eliminate the possibility of misidentifying particular cell types.
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